|
|
|
Issue Open Date
|
08-Jul-25
|
|
|
|
Issue Closing Date
|
10-Jul-25
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
-
|
|
|
|
Minimium Application No.
|
|
|
|
|
Issue Size (Shares)
|
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
|
Objective
|
|
(i) to carry out the Offer for Sale of up to [?] Equity Shares of face value of ? 2 each by theSelling Shareholders aggregating up to ? 33,950.00 million; and(ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges.
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
|
|
|
|
Qualified Institutional Buyers
|
|
|
|
|
Retail Individual Investors
|
|
|
|
|
|
|
|
Business Description:
We are an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization(“CRDMO”) with fully integrated operations spanning across drug discovery, development and manufacturing. We are one ofthe few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilitiesacross drug discovery, development, and commercial manufacturing, according to the F&S Report. As a one-stop serviceprovider, we serve a range of customers, encompassing innovator-focused emerging biotech and large pharmaceuticalcompanies globally. We are one of the youngest Indian CRDMO companies and the fastest Indian CRDMO to achieve amilestone of ?10,000 million of revenue within 14 years of operations, reaching this milestone in Fiscal 2021, according to theF&S Report. We also recorded the highest revenue growth in Fiscal 2023 to Fiscal 2024 as compared to our peers in India andglobally, according to the F&S Report.
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
431747949
|
|
|
|
Offered to Public
|
|
|
|
|
Promoter's Holding (Pre-Issue)
|
77.23
|
|
|
|
Promoter's Holding (Post-Issue)
|
|
|
|
|
|
|
|
|
|
|
|
|
Address |
No. 49
F1 & F2
Canara Bank Road
Bommasandra Industrial Area
Phase I
Bommasandra
Bengaluru
,
Karnataka
,
560099
Phone :
080-66724000
Email :
investors.abl@anthembio.com
Website :
www.anthembio.com
|
|
|
|
Registrar |
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B
Plot 31-32
Gachibowli
Financial District
Nanakramguda
Hyderabad
|
|
|
|
Listed at |
|
BSE, NSE
|
|
|
|
Lead Manager |
Citigroup Global Markets India Pvt Ltd.
JM Financial Ltd.
JP Morgan India Pvt Ltd
Nomura Financial Advisory & Securities (India) Pvt Ltd.
|
|
|
|
Promoters |
Ajay Bhardwaj
Ganesh Sambasivam
Ishaan Bhardwaj
K Ravindra Chandrappa
|
|
